Page last updated: 2024-08-24

topotecan and cx 5461

topotecan has been researched along with cx 5461 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Brajanovski, N; Chan, KT; Cullinane, C; Ellis, S; Hannan, KM; Hannan, RD; Kang, J; Madhamshettiwar, PB; Pearson, RB; Sanij, E; Sheppard, KE; Simpson, KJ; Tancock, MRC; Xuan, J; Yan, S1

Other Studies

1 other study(ies) available for topotecan and cx 5461

ArticleYear
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    British journal of cancer, 2021, Volume: 124, Issue:3

    Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Genes, BRCA2; Homologous Recombination; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Naphthyridines; Neoplasm Grading; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; RNA Interference; RNA Polymerase I; Topoisomerase I Inhibitors; Topotecan

2021